Vera Therapeutics, Inc. VERA
Vera Therapeutics, Inc. (Nasdaq: VERA) is a cardio-renal-metabolic drug developer. Its lead program, TRUTAKNA (atacicept-vymj), is in Phase 2 for Immunoglobulin A nephropathy (IgAN). Its next catalyst on record is atacicept: Additional PIONEER Phase 2 trial results (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: atacicept — Additional PIONEER Phase 2 trial results (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TRUTAKNA (atacicept-vymj) | Immunoglobulin A nephropathy (IgAN) | protein/peptide | Approved |
| atacicept | Primary membranous nephropathy (pMN), FSGS, MCD | protein/peptide | Phase 2 |
| MAU868 | Reactivated BK virus infections | antibody | Phase 2 |
| VT-109 | Autoimmune disease (BAFF/APRIL inhibitor) | protein/peptide | Pre-clinical |
Recent results and decisions
- Nov 5, 2026met ORIGIN 3 final efficacy analysis showed stabilization of kidney function and 76% reduction in risk of composite kidney disease progression versus placebo through two years, meeting all prespecified endpoints.
TRUTAKNA met all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events.
Filing - Nov 5, 2026positive Presented interim results from the adult IgAN and pMN cohorts of the Phase 2 PIONEER basket trial, supporting continued investigation of atacicept in antibody-mediated glomerular diseases.
These interim results support the continued investigation of atacicept in antibody-mediated glomerular diseases.
Filing - Nov 3, 2026submitted Completed supplemental BLA submission to the FDA on November 3, 2026 for full approval of TRUTAKNA in adults with primary IgAN, with potential full approval expected in mid-2027.
Completed supplemental Biologics License Application (sBLA) submission to the FDA on November 3, 2026 for full approval of TRUTAKNA in adults with primary IgAN, based on the ORIGIN 3 final efficacy analysis.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.